NASDAQ · ARTV
Artiva Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARTV: Nov 11, 2026
Artiva Biotherapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.54. The reported EPS for the same quarter last year was $-0.88.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.54 | $-0.53 | $-0.56 | 3 |
| Dec 2026 | $-0.62 | $-0.60 | $-0.65 | 3 |
| Mar 2027 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Jun 2027 | $-0.63 | $-0.63 | $-0.63 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · NASDAQ.com- RTTNews · Oct 27, 10:58 AM EDTArtiva Halts AlloNK Development, Cuts Workforce By 94%; Stock Down(RTTNews) – Artiva Biotherapeutics (ARTV) has discontinued development of AlloNK (AB-101), its cell therapy for autoimmune diseases, and plans to reduce its workforce by approximately 94% while evaluating strategic alternatives.
- Zacks · Jul 8, 9:40 AM EDTIs Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
- Fintel · May 14, 7:06 AM EDTArtiva Biotherapeutics (ARTV) Price Target Increased by 60.00% to 27.74The average one-year price target for Artiva Biotherapeutics (NasdaqGM:ARTV) has been revised to $27.74 / share. This is an increase of 60.00% from the prior estimate of $17.34 dated April 25, 2026. The price target is an average of many targets provided by an
- RTTNews · May 8, 7:27 AM EDTArtiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise(RTTNews) – Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants.
- RTTNews · Mar 11, 3:31 AM EDTArtiva Posts Wider FY25 Loss, Prepares For Key AlloNK Data In Refractory RA(RTTNews) – Artiva Biotherapeutics, Inc. (ARTV) reported its full year financial results and highlighted continued progress across its natural killer (NK) cell therapy pipeline, led by AlloNK, the company's off-the-shelf NK cell candidate being developed for autoimmune diseases a
- RTTNews · Feb 24, 8:23 AM ESTArtiva Biotherapeutics Names Thad Huston CFO(RTTNews) – Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, Tuesday announced that it has appointed Thad Huston as its Chief Financial Officer.
- RTTNews · Dec 9, 12:04 AM ESTAfter-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance(RTTNews) – Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance.
- Fintel · Nov 12, 7:05 PM ESTHC Wainwright & Co. Maintains Artiva Biotherapeutics (ARTV) Buy RecommendationFintel reports that on November 12, 2025, HC Wainwright & Co. maintained coverage of Artiva Biotherapeutics (NasdaqGM:ARTV) with a Buy recommendation. Analyst Price Forecast Suggests 316.12% Upside
- Fintel · Oct 17, 5:49 PM EDTWedbush Maintains Artiva Biotherapeutics (ARTV) Outperform RecommendationFintel reports that on October 17, 2025, Wedbush maintained coverage of Artiva Biotherapeutics (NasdaqGM:ARTV) with a Outperform recommendation. Analyst Price Forecast Suggests 467.08% Upside
- NASDAQ.com · Oct 17, 8:29 AM EDTPre-Market Most Active for Oct 17, 2025 : BITF, SQQQ, ARTV, IONZ, TSLL, CREV, NIO, GWH, BBAI, IONQ, QBTS, LACThe NASDAQ 100 Pre-Market Indicator is down -62.24 to 24,595. The total Pre-Market volume is currently 439,282,825 shares traded.The following are the most active stocks for the pre-market session: Bitfarms Ltd. (BITF) is -0.2688 at $5.01, with 40,616,120 shares traded. As repor
- Fintel · Oct 17, 8:04 AM EDTNeedham Reiterates Artiva Biotherapeutics (ARTV) Buy RecommendationFintel reports that on October 17, 2025, Needham reiterated coverage of Artiva Biotherapeutics (NasdaqGM:ARTV) with a Buy recommendation. Analyst Price Forecast Suggests 467.08% Upside
- The Motley Fool · Aug 6, 9:20 PM EDTArtiva (ARTV) Q2 Loss Widens 19.7%Net loss per share (GAAP) was $(0.87) for Q2 2025, wider than the consensus estimate of $(0.81).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Artiva Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.